Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine
- 27 April 2004
- journal article
- research article
- Published by Wiley in Journal of Computational Chemistry
- Vol. 25 (10) , 1286-1294
Abstract
Gemcitabine (2′,2′‐difluoro‐2′‐deoxycytidine, dFdC) is a very promising anticancer drug, already approved for clinical use in three therapeutic indications. It is metabolized intracellularly to 5′‐diphosphate (dFdCDP), which is known to be a potent inhibitor of ribonucleotide reductase (RNR). Although several nucleotide analogs show in vitro capacity of RNR inactivation, none has shown the in vivo efficacy of dFdCDP. Accordingly, the experimental data suggests that its mechanism of inhibition is different from the other known RNR suicide inhibitors. Enzyme inhibition in the absence of reductive species leads to complete loss of the essential radical in subunit R2, and formation of a new nucleotide‐based radical. Interestingly, however, the presence of the reductants does not prevent inhibition—the radical is not lost but the targeted subunit of RNR becomes R1, which is inactivated possibly by alkylation. We have conducted a theoretical study, which led us to the first proposal of a possible mechanism for RNR inhibition by dFdCDP in the absence of reductants. This mechanism turned out to be very similar to the natural substrate reduction pathway and only deviates from the natural course after the formation of the well‐known disulphide bridge. This deviation is caused precisely by the F atom in the β‐face, only present in this inhibitor. The essential radical in R2 is lost, and so is the enzyme catalytic activity. The nucleotide‐based radical that constitutes the end product of our mechanism has been suggested in the literature as a possible candidate for the one detected experimentally. In fact, all experimental data available has been reproduced by the theoretical calculations performed here. © 2004 Wiley Periodicals, Inc. J Comput Chem 25: 1286–1294, 2004Keywords
This publication has 37 references indexed in Scilit:
- Theoretical Studies on the Mode of Inhibition of Ribonucleotide Reductase by 2′‐Substituted Substrate AnaloguesChemistry – A European Journal, 2003
- Theoretical study of ribonucleotide reductase mechanism-based inhibition by 2?-azido-2?-deoxyribonucleoside 5?-diphosphatesJournal of Computational Chemistry, 2003
- Theoretical Studies on the Mechanism of Inhibition of Ribonucleotide Reductase by (E)-2‘-Fluoromethylene-2‘-deoxycitidine-5‘-diphosphateJournal of the American Chemical Society, 2003
- Novel therapies for renal cell carcinoma – an updateExpert Opinion on Investigational Drugs, 2003
- Overview of gemcitabine triplets in metastatic bladder cancerCritical Reviews in Oncology/Hematology, 2003
- The Conserved Active Site Asparagine in Class I Ribonucleotide Reductase Is Essential for CatalysisJournal of Biological Chemistry, 2002
- Very Stable Ribonucleotide Substrate Radical Relevant for Class I Ribonucleotide ReductaseThe Journal of Physical Chemistry B, 2000
- Theoretical Study of the Substrate Mechanism of Ribonucleotide ReductaseJournal of the American Chemical Society, 1998
- On the accuracy of density functionals and their basis set dependence: An extensive study on the main group homonuclear diatomic molecules Li2 to Br2Journal of Computational Chemistry, 1995
- Location of the redox-active thiols of ribonucleotide reductase: sequence similarity between the Escherichia coli and Lactobacillus leichmannii enzymesBiochemistry, 1987